Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Tamoxifen treatment in breast cancer patients is associated with increased risk of endometrial malignancies. Significantly, higher AGR2 expression was found in endometrial cancers that developed in women previously treated with tamoxifen compared to those who had not been exposed to tamoxifen. An association of elevated AGR2 level with myometrial invasion occurrence and invasion depth was also found. In vitro analyses identified a stimulatory effect of AGR2 on cellular proliferation. Although adverse tamoxifen effects on endometrial cells remain elusive, our work identifies elevated AGR2 as a candidate tamoxifen-dependent mechanism of action responsible for increased incidence of endometrial cancer.

Original publication




Journal article


Cancer Invest

Publication Date





313 - 324


AGR2, Breast cancer, Endometrial cancer, Tamoxifen, A549 Cells, Adenocarcinoma, Antineoplastic Agents, Hormonal, Cell Movement, Cell Proliferation, Cell Transformation, Neoplastic, Endometrial Neoplasms, Endometrium, Female, Humans, MCF-7 Cells, Mucoproteins, Neoplasm Invasiveness, Oncogene Proteins, Proteins, RNA Interference, Retrospective Studies, Risk Factors, Signal Transduction, Tamoxifen, Transfection, Up-Regulation